Skip to main content
Evidence Snapshot

Prolyl endopeptidase FAP

CHEMBL4683 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:32Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4683
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prolyl endopeptidase FAP as ChEMBL target CHEMBL4683, mapped to UniProt Q12884. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prolyl endopeptidase FAP
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4683
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q12884
Prolyl endopeptidase FAP
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Prolyl endopeptidase FAP matters

As of 2026-09-13

Prolyl endopeptidase FAP is reviewed as Prolyl endopeptidase FAP (UniProt Q12884); Prolyl endopeptidase FAP shows clinical signal disease relevance led by colorectal cancer. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 819 compounds, and 124 assays, with lead potency reaching pChEMBL 10.1.

Disease context
colorectal cancer

Prolyl endopeptidase FAP shows clinical signal disease relevance led by colorectal cancer. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include F19 131I.

Start review with colorectal cancer because it currently carries clinical signal support. Linked drugs include F19 131I. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 819 compounds, and 124 assays for this target. The dominant activity type is IC50. CHEMBL4877950 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL4877950 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Prolyl endopeptidase FAP matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q12884, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why colorectal cancer is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

819
Total Compounds
124
Total Assays
5
Approved Drugs
IC50: 859.0, KI: 77.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4877950
 10.1 IC50 —
No preferred name
CHEMBL4878759
 9.9 IC50 —
No preferred name
CHEMBL4864809
 9.7 IC50 —
No preferred name
CHEMBL4853661
 9.7 IC50 —
No preferred name
CHEMBL5569730
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
LINAGLIPTIN
CHEMBL237500
 2011
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:32Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4683